{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:01:40Z","timestamp":1791932500405,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ekir.2025.07.028","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:56:25Z","timestamp":1753944985000},"page":"3318-3331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD"],"prefix":"10.1016","volume":"10","author":[{"given":"Janaka","family":"Karalliedde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Winocour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen A.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parijat","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Loudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritwika","family":"Mallik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagen","family":"Zac-Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Bellary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Goldet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Dhatariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.07.028_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.028_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14769","article-title":"Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease","volume":"39","author":"Karalliedde","year":"2022","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group","volume":"349","author":"Chaturvedi","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.028_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1524-6175.2002.00749.x","article-title":"Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ekir.2025.07.028_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 5","key":"10.1016\/j.ekir.2025.07.028_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.15765","article-title":"Chronic kidney disease in type 2 diabetes: the size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial","volume":"26","author":"Chaudhry","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.07.028_bib10","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1080\/07853890.2020.1841281","article-title":"The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection","volume":"53","author":"Brown","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib11","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.028_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2025.07.028_bib13","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.07.028_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ekir.2023.01.040","article-title":"Narrative review of glycemic management in people with diabetes on peritoneal dialysis","volume":"8","author":"Wijewickrama","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.07.028_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15027","article-title":"Management of adults with diabetes on dialysis: summary of recommendations of the Joint British Diabetes Societies guidelines 2022","volume":"40","author":"Frankel","year":"2023","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/dme.12859","article-title":"Comparison of the heart failure risk stratification performance of the CKD-EPI equation and the MDRD equation for estimated glomerular filtration rate in patients with type 2 diabetes","volume":"33","author":"Wang","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib17","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.028_bib18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00125-011-2085-9","article-title":"The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease","volume":"54","author":"Nair","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2025.07.028_bib19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bmj.39560.442095.AD","article-title":"Management of type 2 diabetes: summary of updated NICE guidance","volume":"336","author":"Home","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.07.028_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib24","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.028_bib25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2168.2000.01497.x","article-title":"Fournier\u2019s gangrene: a review of 1726 cases","volume":"87","author":"Eke","year":"2000","journal-title":"Br J Surg"},{"key":"10.1016\/j.ekir.2025.07.028_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/dom.13900","article-title":"Fournier\u2019s gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials","volume":"22","author":"Silverii","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.07.028_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 inhibitors and the risk of hospitalization for Fournier\u2019s gangrene: a nested case-control study","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther"},{"issue":"issue 7","key":"10.1016\/j.ekir.2025.07.028_bib28","article-title":"Drug Safety Update","volume":"12","year":"2019","journal-title":"Department of Health and Social Care"},{"key":"10.1016\/j.ekir.2025.07.028_bib29","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.07.028_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.07.028_bib31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.07.028_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.07.028_bib33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2025.07.028_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2025.07.028_bib35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12882-025-03985-9","article-title":"Finerenone in the management of diabetes kidney disease","volume":"26","author":"De","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.07.028_bib37","article-title":"Antifibrotic renal role of mineralcorticoid receptor antagonists","volume":"36","author":"Ocello","year":"2019","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.ekir.2025.07.028_bib38","article-title":"Current management of chronic kidney disease in type-2 diabetes-A tiered approach: an overview of the joint Association of British Clinical Diabetologists and Uk Kidney association (ABCD-UKKA) guidelines","volume":"42","author":"Dasgupta","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib39","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2025.07.028_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","article-title":"A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes","volume":"20","author":"Yoshida","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ekir.2025.07.028_bib41","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: A health-economic analysis of DAPA-CKD","volume":"17","author":"McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.028_bib42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","article-title":"Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom","volume":"27","author":"Ramos","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.ekir.2025.07.028_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/dom.15997","article-title":"Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States","volume":"27","author":"Zheng","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.07.028_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00125-022-05832-0","article-title":"Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis","volume":"66","author":"Morton","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2025.07.028_bib45","series-title":"Evidence Review A for SGLT2 Inhibitors for People With Chronic Kidney Disease and Type 2 Diabetes: Type 2 Diabetes in Adults: Management: evidence Review A","year":"2021"},{"key":"10.1016\/j.ekir.2025.07.028_bib46","article-title":"Guideline Committee. Type 2 diabetes: summary of updated NICE guidance","volume":"377","author":"Moran","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.07.028_bib47","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3390\/pharmaceutics15051343","article-title":"The pillars for renal disease treatment in patients with type 2 diabetes","volume":"15","author":"Kearney","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ekir.2025.07.028_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15153","article-title":"Inequalities in the management of diabetic kidney disease in UK primary care: a cross-sectional analysis of a large primary care database","volume":"41","author":"Phillips","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2025.07.028_bib49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:32:21Z","timestamp":1760002341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2468024925004723"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.07.028","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}